Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

Por Sznol, Mario, Chen, Lieping
Publicado em 2013

Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant

Por Cecchini, Michael, Sznol, Mario, Seropian, Stuart
Publicado no J Immunother Cancer (2015)

Melanoma: A model for testing new agents in combination therapies

Por Ascierto, Paolo A, Streicher, Howard Z, Sznol, Mario
Publicado em 2010

Blockade of the B7-H1/PD-1 Pathway for Cancer Immunotherapy

Por Flies, Dallas B., Sandler, Britt J., Sznol, Mario, Chen, Lieping
Publicado em 2011

Use of preferentially replicating bacteria for the treatment of cancer

Por Sznol, Mario, Lin, Stanley L., Bermudes, David, Zheng, Li-mou, King, Ivan
Publicado em 2000

Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies

Por Kunos, Charles A., Chu, Edward, Beumer, Jan H., Sznol, Mario, Ivy, S. Percy
Publicado no Cancer Chemother Pharmacol (2016)

Phase I Trial of Triapine–Cisplatin–Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers

Por Kunos, Charles A., Chu, Edward, Makower, Della, Kaubisch, Andreas, Sznol, Mario, Ivy, Susan Percy
Publicado no Front Oncol (2017)

Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy

Por Hughes, Jing, Vudattu, Nalini, Sznol, Mario, Gettinger, Scott, Kluger, Harriet, Lupsa, Beatrice, Herold, Kevan C.
Publicado no Diabetes Care (2015)

Combination immunotherapy: Where do we go from here?

Por Overacre, Abigail E., Kurtulus, Sema, Sznol, Mario, Pardoll, Drew M., Anderson, Ana, Vignali, Dario A. A.
Publicado no J Immunother Cancer (2015)

Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer

Por Dhodapkar, Kavita, Verma, Rakesh, Sznol, Mario, Boddupalli, Chandra Sekhar, Gettinger, Scott, Kluger, Harriet, Dhodapkar, Madhav, Das, Rituparna
Publicado no J Immunother Cancer (2014)

Tissue resident memory T cells create genetically distinct immune microenvironments within melanoma metastasis

Por Dhodapkar, Kavita, Bar, Noffar, Boddupalli, Chandra Sekhar, Kadaveru, Krishna, Mai, Zifeng, Deng, Yanhong, Sznol, Mario, Dhodapkar, Madhav
Publicado no J Immunother Cancer (2015)

Chitinase-like Proteins in Lung Injury, Repair, and Metastasis

Por Lee, Chun Geun, Dela Cruz, Charles S., Ma, Bing, Ahangari, Farida, Zhou, Yang, Halaban, Ruth, Sznol, Mario, Elias, Jack A.
Publicado em 2012

A PHASE I STUDY OF THE NOVEL RIBONUCLEOTIDE REDUCTASE INHIBITOR 3-AMINOPYRIDINE-2-CARBOXALDEHYDE THIOSEMICARBAZONE (3-AP, TRIAPINE®) IN COMBINATION WITH THE NUCLEOSIDE ANALOG FLUDA...

Por Karp, Judith E., Giles, Francis J., Gojo, Ivana, Morris, Lawrence, Greer, Jacqueline, Johnson, Bonny, Thein, Mya, Sznol, Mario, Low, Jennifer
Publicado em 2007

A phase II trial of dasatinib in advanced melanoma

Por Kluger, Harriet M., Dudek, Arkadiuz Z., McCann, Carrie, Ritacco, Jean, Southard, Nadine, Jilaveanu, Lucia B., Molinaro, Annette, Sznol, Mario
Publicado em 2010

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

Por Rubinstein, Jill C, Sznol, Mario, Pavlick, Anna C, Ariyan, Stephan, Cheng, Elaine, Bacchiocchi, Antonella, Kluger, Harriet M, Narayan, Deepak, Halaban, Ruth
Publicado em 2010

Plasma markers for identifying patients with metastatic melanoma

Por Kluger, Harriet M., Hoyt, Kathleen, Bacchiocchi, Antonella, Mayer, Tina, Kirsch, Jonathan, Kluger, Yuval, Sznol, Mario, Ariyan, Stephan, Molinaro, Annette, Halaban, Ruth
Publicado em 2011

The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization

Por Kluger, Harriet M, McCarthy, Mary M, Alvero, Ayesha B, Sznol, Mario, Ariyan, Stephan, Camp, Robert L, Rimm, David L, Mor, Gil
Publicado em 2007

Genome-wide screen of promoter methylation identifies novel markers in melanoma

Por Koga, Yasuo, Pelizzola, Mattia, Cheng, Elaine, Krauthammer, Michael, Sznol, Mario, Ariyan, Stephan, Narayan, Deepak, Molinaro, Annette M., Halaban, Ruth, Weissman, Sherman M.
Publicado em 2009

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF(WT) melanoma cells

Por Halaban, Ruth, Zhang, Wengeng, Bacchiocchi, Antonella, Cheng, Elaine, Parisi, Fabio, Ariyan, Stephan, Krauthammer, Michael, McCusker, James P, Kluger, Yuval, Sznol, Mario
Publicado em 2010

A Melanoma Brain Metastasis with a Donor-Patient Hybrid Genome following Bone Marrow Transplantation: First Evidence for Fusion in Human Cancer

Por Lazova, Rossitza, LaBerge, Greggory S., Duvall, Eric, Spoelstra, Nicole, Klump, Vincent, Sznol, Mario, Cooper, Dennis, Spritz, Richard A., Chang, Joseph T., Pawelek, John M.
Publicado em 2013